Maxigen Biotech Inc. reported earnings results for the second quarter and six months ended June 30, 2022. For the second quarter, the company reported sales was TWD 154.23 million compared to TWD 121.07 million a year ago. Net income was TWD 33.49 million compared to TWD 21.39 million a year ago. Basic earnings per share from continuing operations was TWD 0.3909 compared to TWD 0.2818 a year ago. Diluted earnings per share from continuing operations was TWD 0.3909 compared to TWD 0.2818 a year ago.
For the six months, sales was TWD 277.49 million compared to TWD 232.08 million a year ago. Net income was TWD 54.03 million compared to TWD 43.01 million a year ago. Basic earnings per share from continuing operations was TWD 0.6364 compared to TWD 0.5636 a year ago. Diluted earnings per share from continuing operations was TWD 0.6364 compared to TWD 0.5636 a year ago.